Newsroom

Sorted by: Latest
-

Trends and Strategies Shaping the $4 Billion Narcolepsy Treatment Market, 2025-2032: Drug Classes, Disorder Types, Age Groups, Distribution Channels, Regions, Key Companies - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Narcolepsy Treatment Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. Senior leaders in the narcolepsy treatment market face an industry defined by technological advancement, shifting care expectations, and complex policy demands. Navigating this environment requires informed decision-making and operational agility to respond to rapid sector evolution. Narcolepsy Treatment Market Snapshot The global narcolepsy treatmen...
-

Swisslog Healthcare Appoints Maria Garces as Vice President of Product Management

BROOMFIELD, Colo.--(BUSINESS WIRE)--Swisslog Healthcare, a leading supplier of transport and pharmacy automation solutions, announces the appointment of Maria Garces as Vice President of Product Management. Garces brings deep experience in global product management, strategy, and business development across healthcare and technology sectors. In her new role, Garces will lead product management initiatives, develop strategic roadmaps, and drive innovation across Swisslog Healthcare's portfolio o...
-

Did You Lose Money in Perrigo Company? PRGO Stockholders Should Contact Robbins LLP for Information About Their Rights Against PRGO.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Perrigo Company (NYSE: PRGO) provides over-the-counter health and wellness solutions in the U.S., Europe, and internationally. What is the class period? February 27, 2024 - November 4, 2025 What is the Case About? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who acquired Perrigo securities during the class period because the Company allegedly misled investors regarding the value of its infant formula...
-

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Skye Bioscience, Inc. (NYSE: SKYE) is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors (“GPCRs”) to treat obesity, overweight, and metabolic diseases. The Company’s lead product candidate is nimacimab. What is the class period? November 4, 2024 - October 3, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors...
-

Location-Based Entertainment Market Forecast Report 2025-2030 - Integration of Big Data Analytics Platforms Capturing In-Venue Customer Behavior are Optimizing Attraction Layouts - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Location-Based Entertainment Market - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. The location-based entertainment market is rapidly transforming the guest experience landscape, blending immersive technologies, advanced analytics, and creative design to deliver interactive, narrative-driven environments. As venues and operators adapt to shifting audience expectations, this market presents new opportunities and operational...
-

Cintas Corporation annonce annonce ses résultats financiers du deuxième trimestre de l'exercice 2026

CINCINNATI--(BUSINESS WIRE)--Cintas Corporation (Nasdaq : CTAS) publie aujourd'hui les résultats de son deuxième trimestre de l'exercice 2026 clos le 30 novembre 2025. Le revenu du deuxième trimestre de l’exercice 2026 s’établit à 2,80 milliards de dollars, contre 2,56 milliards de dollars au deuxième trimestre de l’exercice précédent, soit une hausse de 9,3 %. La croissance du revenu au cours du trimestre a été positivement impactée de 0,7 % en raison des acquisitions. Le taux de croissance or...
-

JHX Deadline: Rosen Law Firm Urges James Hardie Industries plc (NYSE: JHX) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors there is a class action lawsuit on behalf of purchasers of common stock of James Hardie Industries plc (NYSE: JHX) between May 20, 2025 through August 18, 2025, both dates inclusive (the “Class Period”). James Hardie provides exterior home and outdoor living solutions. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm i...
-

Have You Incurred Financial Losses Due to Jayud Global Logistics Limited Stock Drop? Contact Robbins LLP for Information About the Action You Can Take Against JYD.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Jayud Global Logistics Limited (NASDAQ: JYD) claims to provide a range of worldwide cross-border supply chain solution services. What is the Class Period? April 21, 2023 - April 30, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Jayud securities during the class period because the Company allegedly engaged in a fraudulent stock promotion s...
-

Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans...
-

CyberArk獲得IDC MarketScape《2025年全球身分安全整合解決方案供應商評估》頒予「領導者」榮銜

麻薩諸塞州，紐頓 & 以色列，佩塔提克瓦--(BUSINESS WIRE)--(美國商業資訊)-- CyberArk (NASDAQ: CYBR ) 是身分安全的全球翹楚。該公司今天宣布獲得IDC MarketScape《2025年全球身分安全整合解決方案供應商評估》(Worldwide Integrated Solutions for Identity Security 2025) 頒予「領導者」榮銜。CyberArk透過其統一平台擴大動態權限控制及於所有身分類型，提高企業效率並簡化安全運作。 IDC MarketScape在這份報告中指出：「身分安全市場在過去兩年間發生的變化之多，近十年所未見。供應商正進入一個新階段，其不同之處是智慧技術興起，而且這些技術目前尚未接受任何產業標準的明確規範。儘管設計各有千秋，但這些新型身份和存取管理 (IAM) 解決方案主要側重於提高漏洞和威脅管理的可見性，以及自動化和預測性的攻擊偵測能力。」這份報告還指出：「CyberArk在統一框架內處理這些不斷變化的身份類型，增強大規模管理權限、降低營運複雜性、並在企業採用先進技術時保持安全連續性的能力。」...